MedPath
NMPA Approval

Belimumab powder for concentrate for solution for infusion

S20190032

December 10, 2019

S20190032

Drug Information

注射用贝利尤单抗

倍力腾

倍力腾

注射剂

120mg/瓶

生物制品

December 10, 2019

July 11, 2024

Company Information

Applicant Company

12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

Manufacturing Company

glaxosmithkline manufacturing s.p.a.

Strada Provinciale Asolana no.90,San Polo di Torrile,Parma 43056,Italy

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

注射用贝利尤单抗 - NMPA 批准文号 | MedPath